Get the Stockscreener App
0.00
100.00%
-9.81
Allovir Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
AlloVir Inc is a biopharmaceutical company. The company focuses on developing allogeneic T-cell therapies to combat viral diseases. Their proprietary virus-specific T cell VST therapy platform enables the creation of off-the-shelf VSTs, therapy platform allows AlloVir to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. This included: (1) posoleucel (ALVR105), an investigational off-the-shelf multi-virus-specific T cell therapy. (2) ALVR106, an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by four respiratory viruses. (3) ALVR107, an allogeneic, off-the-shelf VST therapy candidate designed to target hepatitis B (HBV).
See More
Previous Close:
$9.81
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$47.48M
Revenue:
-
Net Income/Loss:
$-168.86M
P/E Ratio:
0.00
EPS:
-1.68
Net Cash Flow:
$-125.29M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$24.15
Allovir Inc Stock (ALVR) Company Profile
Name
Allovir Inc
Sector
Industry
Phone
(617) 433-2605
Address
1100 WINTER STREET, WALTHAM
Compare ALVR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVR
Allovir Inc
|
0.00 | 47.48M | 0 | -168.86M | -125.29M | -1.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Allovir Inc Stock (ALVR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-26-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-22-23 | Downgrade | JP Morgan | Overweight → Underweight |
| Dec-22-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-22-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-18-23 | Initiated | BofA Securities | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Aug-24-20 | Initiated | JP Morgan | Overweight |
| Aug-24-20 | Initiated | Morgan Stanley | Overweight |
| Aug-24-20 | Initiated | SVB Leerink | Outperform |
View All
Allovir Inc Stock (ALVR) Latest News
Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Investors to Connect - ACCESS Newswire
Allovir (NASDAQ:KLRS) Rating Increased to Hold at Wall Street Zen - Defense World
Deadline to Claim Your Payout from the AlloVir Settlement Is in 2 Months - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
AlloVir, Inc. (NASDAQ:ALVR) Stake Lowered by Two Sigma Investments LP - Defense World
AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Caribou Biosciences (NASDAQ:CRBU) versus AlloVir (NASDAQ:ALVR) Critical Contrast - Defense World
Squarepoint Ops LLC Invests $142,000 in AlloVir, Inc. (NASDAQ:ALVR) - Defense World
Allovir (NASDAQ:KLRS) Cut to Sell at Wall Street Zen - Defense World
Jane Street Group LLC Buys 39,808 Shares of AlloVir, Inc. (NASDAQ:ALVR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against AlloVir Inc. (ALVR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Two Sigma Advisers LP Sells 11,800 Shares of AlloVir, Inc. (NASDAQ:ALVR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Stockholders to Connect - ACCESS Newswire
Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities - TradingView
Millennium Management LLC Sells 251,018 Shares of AlloVir, Inc. (NASDAQ:ALVR) - Defense World
Wall Street Zen Upgrades Allovir (NASDAQ:KLRS) to Hold - MarketBeat
BNP Paribas Financial Markets Acquires New Holdings in AlloVir, Inc. (NASDAQ:ALVR) - Defense World
AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Allovir (NASDAQ:KLRS) Upgraded to “Hold” at Wall Street Zen - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Investors to Inquire about Securities Investigation - ACCESS Newswire
Kalaris: Phase 1 Trial for TH103 Advances Following AlloVir Merger and Other Important Updates - TradingView
Allovir (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen - Defense World
Deadline to Claim Your Payout from the AlloVir $ALVR Settlement Is in 3 Months - TradingView
AlloVir ($ALVR) Is Paying a Settlement to Investors — Here’s How to Get Your Share - TradingView
Kalaris Therapeutics, Inc. SEC 10-Q Report - TradingView
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights - The Manila Times
Kalaris Eyes Breakthrough in AMD Treatment: Phase 1 Trial Progress and $101M War Chest Revealed in Q1 Earnings - Stock Titan
Shareholders that lost money on AlloVir, Inc.(ALVR) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir LawsuitALVR - ACCESS Newswire
AlloVir, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your RightsALVR - ACCESS Newswire
Lost Money on AlloVir, Inc.(ALVR)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Shareholders that lost money on AlloVir, Inc.(ALVR) should contact Levi & Korsinsky about pending Class ActionALVR - ACCESS Newswire
Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineALVR - ACCESS Newswire
Renaissance Technologies LLC Trims Stock Position in AlloVir, Inc. (NASDAQ:ALVR) - Defense World
DEADLINE ALERT: Bernstein Liebhard LLP Reminds AlloVir, Inc. Investors of Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineALVR - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
Halper Sadeh LLP, AlloVir, Inc., Avid Bioservices, Inc., EMCORE Corporation - The Bradford Era
Halper Sadeh LLP, Aerovate Therapeutics, Inc., Staffing 360 Solutions, Inc., Allovir - The Bradford Era
AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-The-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses - marketscreener.com
William Blair Initiates Kalaris Therapeutics With Outperform Rating - MarketScreener
(ALVR) Technical Data - news.stocktradersdaily.com
Kalaris Therapeutics appoints new board chair By Investing.com - Investing.com Canada
The Gross Law Firm Notifies Shareholders of AlloVir, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2024(NASDAQ: ALVR) - MarketScreener
Kalaris Therapeutics appoints new board chair - Investing.com India
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee - The Manila Times
Kalaris Expands Board Of Directors Appointing Leone Patterson As Chair Of Audit Committee - MarketScreener
Allovir Inc Stock (ALVR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):